Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>Events>This Event
  Events - April 2014


Biosimilars and Biobetters USA

07 Apr 2014 - 08 Apr 2014 - Iselin, NJ, USA



Bookmark and Share


Through a series of exciting panel discussions, presentations and workshops, delivered by true industry experts and players, this meeting will offer effective strategies and solutions for developing cost effective biosimilars for the future.

Read more:

After the phenomenal success of our Biosimilars and Biobetters event hosted in London in October, the SMi Group is delighted to announce the launch of the Biosimilars & Biobetters Conference in Iselin, New Jersey, USA, in April 2014. Registration is now open.

Through a series of exciting panel discussions, presentations and workshops, delivered by true industry experts and players, the Biosimilars and Biobetters USA conference will offer effective strategies and solutions for developing cost effective biosimilars for the future.

Event’s website: www.smi-online.co.uk/2014biosimilars_usa20.asp 

Benefits of attending:

-      Gain up to date insight into the regulatory landscape and how it is effecting the industry

-      Evaluate commercialization and development strategies to gain a competitive advantage 

-      Calculate possible revenue streams from biosimilar production

-      Discover what lessons have been learned so far and what the future holds 

-      Boost your industry knowledge and relationships by networking and learning from key industry and academic leaders

Key speakers include:

-      Dr Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals

-      Dr John Pakulski, Senior Director, and Head US Biopharmaceutical Regulatory Affairs, Sandoz

-      Rodeina Challand, Executive Director, Biosimilars Development, Scientific Affairs, PRA International

-      Dr Stanley (SeungSuh) Hong, President, Research and Development, Celltrion Inc.

-      Paul Ashton, President & CEO, pSivida

-      Peter Pitts, President, Center for Medicine in the Public Interest (Former FDA Associate Commissioner)

-      Douglas M. Long, Vice President, Industry Relations, IMS Health

-      Dr Rakesh Dixit, Vice President, Research and Development Head, Global Biologics Safety Assessment, MedImmune (AstraZeneca Biologics), and many others. 

Don’t miss a chance to visit 2 interactive post-conference workshops:

A.    Differentiation Strategies for the Generics Industry. Workshop Leader: Asa Cox, Founder & CEO, Generic Pharma 2.0

B.    Launching a Biosimilar in an Innovator v. Generic World. Workshop Leader: Kristie Kuhl, JD, Executive VP, Makovsky

For further information please contact Jonathan Collins on +44 (0)20 7827 6734 or email: pharma@smiconferences.co.uk  



Further information
Scientific News
Head Injury Patients have Protein Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
Exposure to Air Pollution 30 Years Ago Associated with Increased Risk of Death
Exposure to air pollution more than 30 years ago may still affect an individual's mortality risk today, according to new research from Imperial College London.
More Then 1 in 20 U.S. Children have Dizziness and Balance Problems
Researchers at NIH have found that girls have a higher prevalence of dizziness and balance problems compared to boys, 5.7 percent and 5.0 percent.
Biosensors on Demand
New strategy results in custom "designer proteins" for sensing a variety of molecules.
Low-Cost, Portable NQR Spectroscopy
A researcher at Case Western Reserve University is developing a low-cost, portable prototype designed to detect tainted medicines and food supplements that otherwise can make their way to consumers. The technology can authenticate good medicines and supplements.
Structure of Brain Plaques in Huntington's
Researchers at the University of Pittsburgh School of Medicine have shown that the core of the protein clumps found in the brains of people with Huntington's disease have a distinctive structure, a finding that could shed light on the molecular mechanisms underlying the neurodegenerative disorder.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Unique Mechanism for a High-Risk Leukemia
Researchers uncovered the aberrant mechanism underlying a notoriously treatment-resistant acute lymphoblastic leukemia subtype; findings offer lessons for understanding all cancers.
Visualizing a Cancer Drug Target at Atomic Resolution
Using cryo-electron microscopy, researchers were able to view, in atomic detail, the binding of a potential small molecule drug to a key protein in cancer cells.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!